{Reference Type}: Case Reports
{Title}: Drug-induced liver injury secondary to tamoxifen.
{Author}: Subhaharan D;Murphy G;Commins N;Azer M;
{Journal}: BMJ Case Rep
{Volume}: 17
{Issue}: 6
{Year}: 2024 Jun 5
暂无{DOI}: 10.1136/bcr-2024-260098
{Abstract}: Tamoxifen is a non-steroidal selective oestrogen receptor modulator commonly used in the treatment of breast cancer. It is associated with the development of fatty liver and steatohepatitis however drug-induced liver injury is rare. We report a woman in her 50s who developed malaise with an acute moderate aminotransferase elevation without jaundice 6 months after starting tamoxifen. She was not commenced on any other recent drugs and extensive investigation including infective and autoimmune liver screen, cross-sectional imaging and FibroScan were unremarkable. Liver biopsy revealed moderate lobular hepatitis with hepatocyte drop-out. Tamoxifen was ceased and the liver enzymes showed resolution over the following 3 months and improvement of her symptoms.